<?xml version="1.0" encoding="ISO-8859-1"?>
<!DOCTYPE ichicsr SYSTEM "http://www.accessdata.fda.gov/xml/icsr-xml-v2.1.dtd">
<ichicsr lang="en">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4149685_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20130125152628</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>1</safetyreportversion>
		<safetyreportid>PHHY2013US006994</safetyreportid>
		<primarysourcecountry>US</primarysourcecountry>
		<occurcountry>US</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>20130125</transmissiondate>
		<reporttype>1</reporttype>
		<serious>1</serious>
		<seriousnessdeath>1</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>2</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>20130122</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>20130122</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>PHHY2013US006994</companynumb>
		<medicallyconfirm>1</medicallyconfirm>
		<primarysource>
			<reportergivename>Alvin</reportergivename>
			<reportermiddlename>C</reportermiddlename>
			<reporterfamilyname>Bronstein</reporterfamilyname>
			<reporterstreet>American Association of Poison Control Centers, 515 King Street Suite 510</reporterstreet>
			<reportercity>Alexandria</reportercity>
			<reporterstate>VA</reporterstate>
			<reporterpostcode>22314</reporterpostcode>
			<reportercountry>US</reportercountry>
			<qualification>3</qualification>
			<literaturereference>Bronstein A, Spyker D, Cantilena L, Rumack B, Dart R. 2011 Annual Report of the American Association of Poison Control Centers' National Poison Data System. Clinical Toxicology. 2011;50:911-1164</literaturereference>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>--</patientinitial>
			<patientonsetage>64</patientonsetage>
			<patientonsetageunit>801</patientonsetageunit>
			<patientsex>2</patientsex>
			<patientdeath>
				<patientautopsyyesno>3</patientautopsyyesno>
				<patientdeathcause>
					<patientdeathreportmeddraversion>15.1</patientdeathreportmeddraversion>
					<patientdeathreport>Completed suicide</patientdeathreport>
				</patientdeathcause>
			</patientdeath>
			<reaction>
				<primarysourcereaction>Patient died of intentional suspected suicide</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Suicide</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Completed suicide</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionoutcome>5</reactionoutcome>
			</reaction>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>DICLOFENAC</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationnumb>19-201</drugauthorizationnumb>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugdosagetext>UNK UKN, UNK</drugdosagetext>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>DICLOFENAC</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Completed suicide</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Completed suicide</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>PANTOPRAZOLE</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugdosagetext>UNK UKN, UNK</drugdosagetext>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>PANTOPRAZOLE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Completed suicide</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Completed suicide</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>POTASSIUM CHLORIDE</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugdosagetext>UNK UKN, UNK</drugdosagetext>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>POTASSIUM CHLORIDE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Completed suicide</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Completed suicide</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>DESIPRAMINE</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugdosagetext>UNK UKN, UNK</drugdosagetext>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>DESIPRAMINE HYDROCHLORIDE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Completed suicide</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Completed suicide</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>DILTIAZEM </medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugdosagetext>UNK UKN, UNK</drugdosagetext>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>DILTIAZEM</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Completed suicide</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Completed suicide</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>VENLAFAXINE HYDROCHLORIDE </medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugdosagetext>UNK UKN, UNK</drugdosagetext>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>VENLAFAXINE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Completed suicide</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Completed suicide</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>LAMOTRIGINE </medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugdosagetext>UNK UKN, UNK</drugdosagetext>
				<drugdosageform>Tablet</drugdosageform>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>LAMOTRIGINE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Completed suicide</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Completed suicide</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>HYDROCHLOROTHIAZIDE</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugdosagetext>UNK UKN, UNK</drugdosagetext>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>HYDROCHLOROTHIAZIDE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Completed suicide</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Completed suicide</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>TRIFLUOPERAZINE </medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugdosagetext>UNK UKN, UNK</drugdosagetext>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>TRIFLUOPERAZINE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Completed suicide</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Completed suicide</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>ESCITALOPRAM </medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugdosagetext>UNK UKN, UNK</drugdosagetext>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>ESCITALOPRAM</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Completed suicide</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Completed suicide</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>LANSOPRAZOLE </medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugdosagetext>UNK UKN, UNK</drugdosagetext>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>LANSOPRAZOLE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Completed suicide</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Completed suicide</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>ROSUVASTATIN </medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugdosagetext>UNK UKN, UNK</drugdosagetext>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>ROSUVASTATIN</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Completed suicide</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Completed suicide</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>NAPROXEN </medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugdosagetext>UNK UKN, UNK</drugdosagetext>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>NAPROXEN</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Completed suicide</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Completed suicide</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>NITROFURANTOIN </medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugdosagetext>UNK UKN, UNK</drugdosagetext>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>NITROFURANTOIN</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Completed suicide</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Completed suicide</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>SOLIFENACIN </medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugdosagetext>UNK UKN, UNK</drugdosagetext>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>SOLIFENACIN</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Completed suicide</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Completed suicide</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>CIPROFLOXACIN </medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugdosagetext>UNK UKN, UNK</drugdosagetext>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>CIPROFLOXACIN</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Completed suicide</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Completed suicide</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>PROGESTIN</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugdosagetext>UNK UKN, UNK</drugdosagetext>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>PROGESTERONE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>ACETAMINOPHEN W/PROPOXYPHENE</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugdosagetext>UNK UKN, UNK</drugdosagetext>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>DEXTROPROPOXYPHENE, PARACETAMOL</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>ACETAMINOPHEN W/HYDROCODONE</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>HYDROCODONE, PARACETAMOL</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>ARMODAFINIL</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugdosagetext>UNK UKN, UNK</drugdosagetext>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>ARMODAFINIL</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>THYROID PREPARATIONS</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugdosagetext>UNK UKN, UNK</drugdosagetext>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>NO INGREDIENTS/SUBSTANCES</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>Case number PHHY2013US006994, is an initial literature report received on 22 Jan 2013. This is the 29th Annual Report of the American Association of Poison Control Centers' (AAPCC) National Poison Data System (NPDS) and provides a listing of fatal cases from their database for drug exposure-related fatal cases. This case refers to a 64-year-old female patient (Table no: 21, Patient No: 1328h). The patient had a chronic exposure to diclofenac (manufacturer unknown), desipramine (manufacturer unknown), diltiazem (extended release, manufacturer unknown), venlafaxine (manufacturer unknown), lamotrigine (manufacturer unknown), hydrochlorothiazide (manufacturer unknown), armodannil (manufacturer unknown), potassium chloride (manufacturer unknown), trifluoperazine (manufacturer unknown), escitalopram (manufacturer unknown), thyroid preparation (manufacturer unknown), pantoprazole (manufacturer unknown), lansoprazole (manufacturer unknown), rovustatin (manufacturer unknown), naproxen (manufacturer unknown), nitrofurantoin (manufacturer unknown), acetaminophen/hydrocodone (manufacturer unknown),  acetaminophen/propoxyphene (manufacturer unknown), solifenacin (manufacturer unknown), ciprofloxacin (manufacturer unknown), and progestin (manufacturer unknown), for an unspecified indication (unknown dose and therapy dates). On an unspecified date, the patient died of intentional suspected suicide. It was unknown whether autopsy was done or not. The causality of death/relative contribution to fatality was reported as undoubtedly responsible to suspect drug.</narrativeincludeclinical>
				<sendercomment>MAC for Diclofenac and desipramine: 
Based on  Review of available reported data does not allow for a proper causality assessment. Reported event suicide is unassessable

MAC for NGX suspects: The review of available reported data does not allow for a proper causality assessment.

MAC for Hydrochlorothiazide, potassium chloride and pantoprazole: Review of available reported data does not allow for a proper causality assessment.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr>
